AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (604.8 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Lynch syndrome pre-screening and comprehensive characterization in a multi-center large cohort of Chinese patients with colorectal cancer

Yan Li1,*Lihong Fan2,*Jianming Zheng3Xiu Nie1Yu Sun4Qin Feng4Shenyi Lian4Wenqi Bai5Weijing Cai6Yanan Yang7Bo Su8Yanfeng Xi9( )Dongmei Lin4 ( )
Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
Department of Respiration Medicine, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200072, China
Department of Pathology, Changhai Hospital of Shanghai, Shanghai 200433, China
Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China
Department of Colorectal Surgery, Shanxi Cancer Hospital, Taiyuan 030013, China
Shanghai Tongshu Biotechnology Co., Ltd, Shanghai 200120, China
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA
Central Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China
Department of Pathology, Shanxi Cancer Hospital, Taiyuan 030013, China

*These authors contributed equally to this work.

Show Author Information

Abstract

Objective

Lynch syndrome (LS) pre-screening methods remain under-investigated in colorectal cancers (CRCs) in Asia. Here, we aimed to systematically investigate LS pre-screening and comprehensively characterize LS CRCs.

Methods

Microsatellite instability (MSI) and germline variants of DNA mismatch repair (MMR) genes were examined in 406 deficient MMR (dMMR) and 250 proficient MMR CRCs. The genetic differences between LS and sporadic CRCs were studied with whole exome sequencing analysis.

Results

The incidence of dMMR in Chinese patients with CRCs was 13.8%. Consistency analysis between MMR immunohistochemistry (IHC) and MSI testing showed the kappa value was 0.758. With next-generation sequencing (NGS), germline variants were detected in 154 CRCs. Finally, 88 patients with CRC were identified as having LS by Sanger sequencing. Among them, we discovered 21 previously unreported pathogenic germline variants of MMR genes. Chinese patients with LS, compared with sporadic CRCs, tended to be early-onset, right-sided, early-stage and mucinous. Overall, the performance of MMR IHC and MSI testing for LS pre-screening was comparable: the area under the ROC curve for dMMR, MSI-H, and MSI-H/L was 0.725, 0.750, and 0.745, respectively. dMMR_MSI-H LS and sporadic CRCs showed substantial differences in somatic genetic characteristics, including different variant frequencies of APC, CREBBP, and KRAS, as well as different enriched pathways of VEGF, Notch, TGFβR, mTOR, ErbB, and Rac protein signal transduction.

Conclusions

MMR IHC and MSI testing were effective methods for LS pre-screening. The revealed clinical and somatic genetic characteristics in LS CRCs may have the potential to improve the performance of LS pre-screening in combination with dMMR/MSI.

Electronic Supplementary Material

Download File(s)
cbm-19-8-1235_ESM.pdf (153.7 KB)

References

1

Boland PM, Yurgelun MB, Boland CR. Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. CA Cancer J Clin. 2018; 68: 217-31.

2

Goverde A, Wagner A, Bruno MJ, Hofstra RMW, Doukas M, van der Weiden MM, et al. Routine molecular analysis for Lynch syndrome among adenomas or colorectal cancer within a national screening program. Gastroenterology. 2018; 155: 1410-15.

3

Samadder NJ, Smith KR, Wong J, Thomas A, Hanson H, Boucher K, et al. Cancer risk in families fulfilling the Amsterdam criteria for Lynch syndrome. JAMA Oncol. 2017; 3: 1697-701.

4

Lok P, Dijk S. Offer daily aspirin to cut risk of colorectal cancer in people with Lynch syndrome, says NICE. BMJ. 2019; 366: l5010.

5

Monahan KJ, Alsina D, Bach S, Buchanan J, Burn J, Clark S, et al. Urgent improvements needed to diagnose and manage Lynch syndrome. BMJ. 2017; 356: j1388.

6

Salvador MU, Truelson MRF, Mason C, Souders B, LaDuca H, Dougall B, et al. Comprehensive paired tumor/germline testing for Lynch syndrome: bringing resolution to the diagnostic process. J Clin Oncol. 2019; 37: 647-57.

7

Hampel H, Pearlman R, Beightol M, Zhao W, Jones D, Frankel WL, et al. Assessment of tumor sequencing as a replacement for Lynch syndrome screening and current molecular tests for patients with colorectal cancer. JAMA Oncol. 2018; 4: 806-13.

8

Engel C, Vasen HF, Seppälä T, Aretz S, Bigirwamungu-Bargeman M, de Boer SY, et al. No difference in colorectal cancer incidence or stage at detection by colonoscopy among 3 countries with different Lynch syndrome surveillance policies. Gastroenterology. 2018; 155: 1400-9.e2.

9

Gallego CJ, Shirts BH, Bennette CS, Guzauskas G, Amendola LM, Horike-Pyne M, et al. Next-Generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a costeffectiveness analysis. J Clin Oncol. 2015; 33: 2084-91.

10

Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, et al. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol. 2019; 37: 286-95.

11

Evrard C, Tachon G, Randrian V, Karayan-Tapon L, Tougeron D. Microsatellite instability: diagnosis, heterogeneity, discordance, and clinical impact in colorectal cancer. Cancers (Basel). 2019; 11: 1567.

12

Georgeson P, Pope BJ, Rosty C, Clendenning M, Mahmood K, Joo JE, et al. Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers. Gut. 2021; 70: 2138-49.

13

Sanz-Garcia E, Argiles G, Elez E, Tabernero J. BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Ann Oncol. 2017; 28: 2648-57.

14

Li D, Hoodfar E, Jiang SF, Udaltsova N, Pham NP, Jodesty Y, et al. Comparison of universal versus age-restricted screening of colorectal tumors for Lynch syndrome using mismatch repair immunohistochemistry: a cohort study. Ann Intern Med. 2019; 171: 19-26.

15

Ballester V, Cruz-Correa M. How and when to consider genetic testing for colon cancer? Gastroenterology. 2018; 155: 955-9.

16

Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology. 2014; 147: 502-26.

17

Xu HX, Zhu P, Zheng YY, Zhang X, Chen YQ, Qiao LC, et al. Molecular screening and clinicopathologic characteristics of Lynchlike syndrome in a Chinese colorectal cancer cohort. Am J Cancer Res. 2020; 10: 3920-34.

18

Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JI, et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal. Cell. 2018; 173: 581-94.e12.

19

Wu B, Lu X, Shen H, Yuan X, Wang X, Yin N, et al. Intratumoral heterogeneity and genetic characteristics of prostate cancer. Int J Cancer. 2020; 146: 3369-78.

20

Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. The clinical phenotype of Lynch syndrome due to germline PMS2 mutations. Gastroenterology. 2008; 135: 419-28.

21

Lagerstedt-Robinson K, Rohlin A, Aravidis C, Melin B, Nordling M, Stenmark-Askmalm M, et al. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population. Oncol Rep. 2016; 36: 2823-35.

22

Jiang W, Cai MY, Li SY, Bei JX, Wang F, Hampel H, et al. Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: high prevalence and unique molecular features. Int J Cancer. 2019; 144: 2161-8.

23

Gong R, He Y, Liu XY, Wang HY, Sun LY, Yang XH, et al. Mutation spectrum of germline cancer susceptibility genes among unselected Chinese colorectal cancer patients. Cancer Manag Res. 2019; 11: 3721-39.

24

Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol. 2017; 35: 1086-95.

25

Nakayama Y, Iijima T, Inokuchi T, Kojika E, Takao M, Takao A, et al. Clinicopathological features of sporadic MSI colorectal cancer and Lynch syndrome: a single-center retrospective cohort study. Int J Clin Oncol. 2021; 26: 1881-9.

26

Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487: 330-7.

27

Dimberg J, Andersson RE, Haglund S. Genomic Profiling of Stage Ⅱ Colorectal cancer identifies candidate genes associated with recurrence-Free survival, tumor location, and differentiation grade. Oncology. 2020; 98: 575-82.

28

Forghanifard MM, Moghbeli M, Raeisossadati R, Tavassoli A, Mallak AJ, Boroumand-Noughabi S, et al. Role of SALL4 in the progression and metastasis of colorectal cancer. J Biomed Sci. 2013; 20: 6.

29

Cajuso T, Hänninen UA, Kondelin J, Gylfe AE, Tanskanen T, Katainen R, et al. Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer. Int J Cancer. 2014; 135: 611-23.

30

Oga T, Yamashita Y, Soda M, Kojima S, Ueno T, Kawazu M, et al. Genomic profiles of colorectal carcinoma with liver metastases and newly identified fusion genes. Cancer Sci. 2019; 110: 2973-81.

31

Feng L, Hong S, Gao J, Li J. Whole-exome sequencing characterized the landscape of somatic mutations and pathways in colorectal cancer liver metastasis. J Oncol. 2019; 2019: 2684075.

32

Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology. 2015; 149: 1177-90.e3.

33

Di J, Yang H, Jiang B, Wang Z, Ji J, Su X. Whole exome sequencing reveals intertumor heterogeneity and distinct genetic origins of sporadic synchronous colorectal cancer. Int J Cancer. 2018; 142: 927-39.

34

Ahadova A, Gallon R, Gebert J, Ballhausen A, Endris V, Kirchner M, et al. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome. Int J Cancer. 2018; 143: 139-50.

35

Engel C, Ahadova A, Seppälä TT, Aretz S, Bigirwamungu-Bargeman M, Bläker H, et al. Associations of pathogenic variants in MLH1, MSH2, and MSH6 with risk of colorectal adenomas and tumors and with somatic mutations in patients with Lynch syndrome. Gastroenterology. 2020; 158: 1326-33.

36

Helderman NC, Bajwa-Ten Broeke SW, Morreau H, Suerink M, Terlouw D, van der Werf TLAS, et al. The diverse molecular profiles of lynch syndrome-associated colorectal cancers are (highly) dependent on underlying germline mismatch repair mutations. Crit Rev Oncol Hematol. 2021; 163: 103338.

37

Zaanan A, Henriques J, Cohen R, Sefrioui D, Evrard C, de la Fouchardiere C, et al. Efficacy of anti-EGFR in microsatellite instability metastatic colorectal cancer depending on sporadic or familial origin. J Natl Cancer Inst. 2021; 113: 496-500.

38

Sinicrope FA. Lynch syndrome-associated colorectal cancer. N Engl J Med. 2018; 379: 764-73.

Cancer Biology & Medicine
Pages 1235-1248
Cite this article:
Li Y, Fan L, Zheng J, et al. Lynch syndrome pre-screening and comprehensive characterization in a multi-center large cohort of Chinese patients with colorectal cancer. Cancer Biology & Medicine, 2022, 19(8): 1235-1248. https://doi.org/10.20892/j.issn.2095-3941.2021.0585

55

Views

0

Downloads

0

Crossref

1

Web of Science

1

Scopus

Altmetrics

Received: 28 October 2021
Accepted: 27 December 2021
Published: 29 August 2022
©2022 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License

Return